SOLID TUMOURS:@0.084848:0.038601:0.266058:0.038601:0.266058:0.019343:0.084848:0.019343:0.011712:0.020438:0.010866:0.005315:0.017498:0.006515:0.010019:0.015405:0.021613:0.020438:0.015405:0.014276:0.011712
56:@0.023705:0.038809:0.044778:0.038809:0.044778:0.019212:0.023705:0.019212:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
Subsequently,  carboplatinum  was substi-:@0.084242:0.096166:0.475148:0.096166:0.475148:0.080410:0.084242:0.080410:0.009583:0.011699:0.013123:0.007466:0.012508:0.013123:0.011699:0.012508:0.011738:0.006523:0.003848:0.010314:0.005330:0.005330:0.004414:0.012450:0.013143:0.005792:0.013123:0.012604:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.005330:0.004414:0.015990:0.013143:0.007466:0.009756:0.007466:0.011699:0.013123:0.007466:0.006523:0.003848:0.006388
tuted  for  cisplatinum  and  the  results did :@0.084242:0.112609:0.480494:0.112609:0.480494:0.096854:0.084242:0.096854:0.006523:0.011699:0.006523:0.012508:0.013181:0.005330:0.004002:0.006042:0.012604:0.005792:0.005330:0.004006:0.012450:0.003848:0.007466:0.013123:0.003848:0.013156:0.006523:0.003848:0.011738:0.011699:0.018049:0.005330:0.004006:0.013143:0.011738:0.013181:0.005330:0.004010:0.006523:0.011738:0.012508:0.005330:0.004008:0.005711:0.012508:0.007466:0.011699:0.003848:0.006523:0.007466:0.009352:0.013181:0.003848:0.013181:0.005330
not differ. As the incidence of renal toxic-:@0.084242:0.129053:0.475140:0.129053:0.475140:0.113297:0.084242:0.113297:0.011738:0.012604:0.006523:0.006465:0.013181:0.003848:0.006102:0.006042:0.012508:0.004378:0.005330:0.006465:0.014239:0.007466:0.006465:0.006523:0.011738:0.012508:0.006465:0.003848:0.011738:0.012450:0.003848:0.013181:0.012508:0.011738:0.012450:0.012508:0.006465:0.012604:0.006042:0.006465:0.005711:0.012508:0.011738:0.013143:0.003848:0.006465:0.006523:0.012604:0.009236:0.003848:0.012450:0.006388
ity is lower with carboplatinum, the stand-:@0.084242:0.145497:0.475156:0.145497:0.475156:0.129741:0.084242:0.129741:0.003848:0.006523:0.010314:0.006081:0.003848:0.007466:0.006081:0.003848:0.012604:0.015990:0.012508:0.005792:0.006069:0.015990:0.003848:0.006523:0.011738:0.006081:0.012450:0.013143:0.005792:0.013123:0.012604:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.005330:0.006071:0.006523:0.011738:0.012508:0.006067:0.007466:0.006523:0.013143:0.011738:0.013181:0.006388
ard of care became carboplatinum and :@0.084242:0.161941:0.480482:0.161941:0.480482:0.146185:0.084242:0.146185:0.013143:0.005677:0.013181:0.007505:0.012604:0.006042:0.007505:0.012450:0.013143:0.005715:0.012508:0.007505:0.013123:0.012508:0.012450:0.013143:0.018049:0.012508:0.007505:0.012450:0.013143:0.005792:0.013123:0.012604:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.007505:0.013143:0.011738:0.013181:0.005330
paclitaxel (colloquially  known as carbo/:@0.084242:0.178385:0.475154:0.178385:0.475154:0.162629:0.084242:0.162629:0.013123:0.013143:0.012450:0.003848:0.003848:0.006523:0.013143:0.009236:0.012508:0.003848:0.009775:0.007100:0.012450:0.012604:0.003848:0.003848:0.012604:0.013123:0.011699:0.003848:0.013143:0.003848:0.003848:0.010314:0.005330:0.004457:0.009660:0.011738:0.012604:0.015990:0.011728:0.009775:0.013143:0.007466:0.009775:0.012450:0.013143:0.005792:0.013123:0.012604:0.008409
taxel). Carboplatinum and docetaxel are :@0.084242:0.194829:0.480511:0.194829:0.480511:0.179073:0.084242:0.179073:0.006523:0.013143:0.009236:0.012508:0.003848:0.007100:0.005330:0.006388:0.015644:0.013143:0.005792:0.013123:0.012604:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388:0.013143:0.011738:0.013181:0.006388:0.013181:0.012604:0.012450:0.012508:0.006523:0.013143:0.009236:0.012508:0.003848:0.006379:0.013143:0.005715:0.012508:0.005330
equivalent to  carboplatinum and pacli-:@0.084242:0.211273:0.475152:0.211273:0.475152:0.195517:0.084242:0.195517:0.012508:0.013123:0.011699:0.003848:0.010660:0.013143:0.003848:0.012508:0.011738:0.006523:0.010564:0.006523:0.012604:0.005330:0.005219:0.012450:0.013143:0.005792:0.013123:0.012604:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.010564:0.013143:0.011738:0.013181:0.010564:0.013123:0.013143:0.012450:0.003848:0.003845:0.006388
taxel.  The difference is in the toxicity pro-:@0.084242:0.227716:0.475144:0.227712:0.475144:0.211956:0.084242:0.211960:0.006523:0.013143:0.009236:0.012508:0.003848:0.005330:0.012432:0.005426:0.008197:0.011738:0.012508:0.005426:0.013181:0.003848:0.006102:0.006042:0.012508:0.005711:0.012508:0.011738:0.012450:0.012508:0.005426:0.003848:0.007466:0.005438:0.003848:0.011738:0.005426:0.006523:0.011738:0.012508:0.005426:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.005426:0.013123:0.005715:0.012604:0.677489
10:@0.134829:0.222093:0.147259:0.222093:0.147259:0.212907:0.134829:0.212907:0.006215:0.006215
file, with more neurotoxicity seen with pa-:@0.084244:0.244156:0.475146:0.244156:0.475146:0.228400:0.084244:0.228400:0.004686:0.004686:0.003848:0.012508:0.005330:0.006381:0.015990:0.003848:0.006523:0.011738:0.006387:0.018049:0.012604:0.005707:0.012508:0.006385:0.011738:0.012508:0.011699:0.005707:0.012604:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.006381:0.007466:0.012508:0.012508:0.011738:0.006381:0.015990:0.003848:0.006523:0.011738:0.006387:0.013123:0.013143:0.006388
clitaxel and more myelosuppression with :@0.084244:0.260600:0.480493:0.260600:0.480493:0.244844:0.084244:0.244844:0.012450:0.003848:0.003848:0.006523:0.013143:0.009236:0.012508:0.003848:0.009102:0.013143:0.011738:0.013181:0.009102:0.018049:0.012604:0.005707:0.012508:0.009102:0.018049:0.010314:0.012508:0.003848:0.012604:0.007466:0.011699:0.013123:0.013123:0.005713:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.009102:0.015990:0.003848:0.006523:0.011738:0.005330
docetaxel.:@0.084244:0.277044:0.185575:0.277044:0.185575:0.261288:0.084244:0.261288:0.013181:0.012604:0.012450:0.012508:0.006523:0.013143:0.009236:0.012508:0.003848:0.005330
The addition of a third or even a fourth :@0.102428:0.293487:0.480532:0.293487:0.480532:0.277731:0.102428:0.277731:0.008197:0.011738:0.012508:0.007010:0.013143:0.013181:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.007023:0.012604:0.006042:0.007023:0.013143:0.007023:0.006523:0.011738:0.003848:0.005675:0.013181:0.007023:0.012604:0.005792:0.007010:0.012508:0.010660:0.012508:0.011738:0.007023:0.013143:0.007023:0.006042:0.012604:0.011699:0.005792:0.006523:0.011738:0.005330
chemotherapy  agent to the carbo-:@0.084244:0.309931:0.475179:0.309931:0.475179:0.294175:0.084244:0.294175:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.014707:0.013143:0.012950:0.012508:0.011738:0.006523:0.020051:0.006523:0.012604:0.020051:0.006523:0.011738:0.012508:0.020051:0.012450:0.013143:0.005792:0.013123:0.012604:0.006388
platinum and taxane backbone has not :@0.084244:0.326375:0.480464:0.326375:0.480464:0.310619:0.084244:0.310619:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.008601:0.013143:0.011738:0.013181:0.008601:0.006523:0.013143:0.009236:0.013143:0.011738:0.012508:0.008601:0.013123:0.013143:0.012450:0.009660:0.013123:0.012604:0.011738:0.012508:0.008601:0.011738:0.013143:0.007466:0.008601:0.011738:0.012604:0.006523:0.005330
improved  outcome,  but  has merely in-:@0.084244:0.342819:0.475163:0.342819:0.475163:0.327063:0.084244:0.327063:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.013181:0.005330:0.006841:0.012604:0.011699:0.006523:0.012450:0.012604:0.018049:0.012508:0.005330:0.005330:0.006821:0.013123:0.011699:0.006523:0.005330:0.006841:0.011738:0.013143:0.007466:0.012180:0.018049:0.012508:0.005711:0.012508:0.003848:0.010314:0.012180:0.003848:0.011738:0.006388
creased the  toxicity.  There  have been :@0.084244:0.359263:0.480507:0.359263:0.480507:0.343507:0.084244:0.343507:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.013181:0.012796:0.006523:0.011738:0.012508:0.005330:0.007449:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.005330:0.005330:0.007456:0.008197:0.011738:0.012508:0.005703:0.012508:0.005330:0.007453:0.011738:0.013143:0.010660:0.012508:0.012796:0.013123:0.012508:0.012508:0.011738:0.005330
multiple trials of this nature, but none has :@0.084244:0.375707:0.480482:0.375707:0.480482:0.359951:0.084244:0.359951:0.018049:0.011699:0.003848:0.006523:0.003848:0.013123:0.003848:0.012508:0.007100:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.007100:0.012604:0.006042:0.007100:0.006523:0.011738:0.003848:0.007466:0.007100:0.011738:0.013143:0.006523:0.011699:0.005707:0.012508:0.005330:0.007100:0.013123:0.011699:0.006523:0.007100:0.011738:0.012604:0.011738:0.012508:0.007087:0.011738:0.013143:0.007466:0.005330
improved survival rates. The use of single-:@0.084244:0.392151:0.475140:0.392151:0.475140:0.376395:0.084244:0.376395:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.013181:0.006966:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.006987:0.005792:0.013143:0.006523:0.012508:0.007466:0.005330:0.006966:0.008197:0.011738:0.012508:0.006966:0.011699:0.007466:0.012508:0.006966:0.012604:0.006042:0.006966:0.007466:0.003848:0.011738:0.012950:0.003848:0.012508:0.006388
agent carboplatinum as opposed to the :@0.084244:0.408594:0.480495:0.408594:0.480495:0.392838:0.084244:0.392838:0.013143:0.012950:0.012508:0.011738:0.006523:0.007964:0.012450:0.013143:0.005792:0.013123:0.012604:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.007974:0.013143:0.007466:0.007986:0.012604:0.013123:0.013123:0.012604:0.007466:0.012508:0.013181:0.007972:0.006523:0.012604:0.007966:0.006523:0.011738:0.012508:0.005330
doublet is sometimes recommended in :@0.084244:0.425038:0.480499:0.425038:0.480499:0.409282:0.084244:0.409282:0.013181:0.012604:0.011699:0.013123:0.003848:0.012508:0.006523:0.012257:0.003848:0.007466:0.012257:0.007466:0.012604:0.018049:0.012508:0.006523:0.003848:0.018049:0.012508:0.007466:0.012257:0.005711:0.012508:0.012450:0.012604:0.018049:0.018049:0.012508:0.011738:0.013181:0.012508:0.013181:0.012257:0.003848:0.011738:0.005330
poor PS patients with multiple comorbidi-:@0.084244:0.441482:0.475159:0.441482:0.475159:0.425726:0.084244:0.425726:0.013123:0.012604:0.012604:0.005792:0.007491:0.011392:0.009583:0.007505:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007505:0.015990:0.003848:0.006523:0.011738:0.007505:0.018049:0.011699:0.003848:0.006523:0.003848:0.013123:0.003848:0.012508:0.007505:0.012450:0.012604:0.018049:0.012604:0.005792:0.013123:0.003848:0.013181:0.003848:0.006388
ties who are unable to tolerate the toxicity :@0.084244:0.457926:0.480497:0.457926:0.480497:0.442170:0.084244:0.442170:0.006523:0.003848:0.012508:0.007466:0.004888:0.015990:0.011738:0.012604:0.004872:0.013143:0.005715:0.012508:0.004876:0.011699:0.011738:0.013143:0.013123:0.003848:0.012508:0.004888:0.006523:0.012604:0.004870:0.006523:0.012604:0.003848:0.012508:0.005792:0.013143:0.006523:0.012508:0.004866:0.006523:0.011738:0.012508:0.004870:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.005330
of this combination. This follows the results :@0.084244:0.474370:0.480497:0.474370:0.480497:0.458614:0.084244:0.458614:0.012604:0.006042:0.006337:0.006523:0.011738:0.003848:0.007466:0.006350:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.006335:0.008197:0.011738:0.003848:0.007466:0.006350:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.007466:0.006350:0.006523:0.011738:0.012508:0.006337:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.007466:0.005330
of ICON 3 where carboplatin and pacli-:@0.084244:0.490814:0.475154:0.490814:0.475154:0.475058:0.084244:0.475058:0.012604:0.006042:0.008659:0.004349:0.015644:0.016722:0.014239:0.008659:0.010660:0.008659:0.015990:0.011738:0.012508:0.005711:0.012508:0.008659:0.012450:0.013143:0.005792:0.013123:0.012604:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.008659:0.013143:0.011738:0.013181:0.008659:0.013123:0.013143:0.012450:0.003848:0.003891:0.006388
taxel as standard of care were compared :@0.084244:0.507258:0.480493:0.507258:0.480493:0.491502:0.084244:0.491502:0.006523:0.013143:0.009236:0.012508:0.003848:0.005176:0.013143:0.007466:0.005176:0.007466:0.006523:0.013143:0.011738:0.013181:0.013143:0.005675:0.013181:0.005176:0.012604:0.006042:0.005176:0.012450:0.013143:0.005713:0.012508:0.005176:0.015990:0.012508:0.005711:0.012508:0.005176:0.012450:0.012604:0.018049:0.013123:0.013143:0.005713:0.012508:0.013181:0.005330
to  single-agent  carboplatin  or  to  a  third :@0.084244:0.523701:0.480482:0.523701:0.480482:0.507945:0.084244:0.507945:0.006523:0.012604:0.005330:0.003868:0.007466:0.003848:0.011738:0.012950:0.003848:0.012508:0.006388:0.013143:0.012950:0.012508:0.011738:0.006523:0.005330:0.003868:0.012450:0.013143:0.005792:0.013123:0.012604:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.005330:0.003877:0.012604:0.005792:0.005330:0.003870:0.006523:0.012604:0.005330:0.003868:0.013143:0.005330:0.003877:0.006523:0.011738:0.003848:0.005673:0.013181:0.005330
arm of  cyclophosphamide,  adriamycin :@0.084244:0.540145:0.480486:0.540145:0.480486:0.524389:0.084244:0.524389:0.013143:0.006325:0.018049:0.013912:0.012604:0.006042:0.005330:0.008571:0.012450:0.010314:0.012450:0.003848:0.012604:0.013123:0.011738:0.012604:0.007466:0.013123:0.011738:0.013143:0.018049:0.003848:0.013181:0.012508:0.005330:0.005330:0.008582:0.013143:0.013181:0.005792:0.003848:0.013143:0.018049:0.010314:0.012450:0.003848:0.011738:0.005330
and cisplatin.  The outcome of all  three :@0.084244:0.556589:0.480474:0.556578:0.480474:0.540822:0.084244:0.540833:0.013143:0.011738:0.013181:0.008621:0.012450:0.003848:0.007466:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.005330:0.012449:0.008621:0.008197:0.011738:0.012508:0.008621:0.012604:0.011699:0.006523:0.012450:0.012604:0.018049:0.012492:0.008621:0.012604:0.006042:0.008621:0.013143:0.003848:0.003848:0.005330:0.003304:0.006523:0.011738:0.005707:0.012508:0.012508:0.192751
11:@0.212260:0.550959:0.224690:0.550959:0.224690:0.541773:0.212260:0.541773:0.006215:0.006215
arms was similar.:@0.084244:0.573022:0.236418:0.573022:0.236418:0.557266:0.084244:0.557266:0.013143:0.006325:0.018049:0.007466:0.005330:0.015990:0.013143:0.007466:0.005330:0.007466:0.003848:0.018049:0.003848:0.003848:0.013143:0.004399:0.005330
ANTI-ANGIOGENIC AGENT:@0.084242:0.606231:0.356629:0.606231:0.356629:0.588416:0.084242:0.588416:0.015822:0.015822:0.008980:0.005987:0.008980:0.015822:0.015822:0.017960:0.005987:0.017960:0.017960:0.011118:0.015822:0.005987:0.016677:0.005987:0.015822:0.017960:0.011118:0.015822:0.008980
There has been no further  improvement :@0.084242:0.623821:0.480492:0.623821:0.480492:0.608065:0.084242:0.608065:0.008197:0.011738:0.012508:0.005703:0.012508:0.009660:0.011738:0.013143:0.007466:0.009660:0.013123:0.012508:0.012508:0.011738:0.009660:0.011738:0.012604:0.009660:0.006042:0.011699:0.005792:0.006523:0.011738:0.012508:0.005792:0.005330:0.004312:0.003848:0.018049:0.013123:0.005715:0.012604:0.010660:0.012508:0.018049:0.012508:0.011738:0.006523:0.005330
in the  outcome of  patients treated with :@0.084242:0.640265:0.480501:0.640265:0.480501:0.624509:0.084242:0.624509:0.003848:0.011738:0.009410:0.006523:0.011738:0.012508:0.005330:0.004068:0.012604:0.011699:0.006523:0.012450:0.012604:0.018036:0.012508:0.009410:0.012604:0.006042:0.005330:0.004070:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.009410:0.006523:0.005711:0.012508:0.013143:0.006523:0.012508:0.013181:0.009410:0.015990:0.003848:0.006523:0.011738:0.005330
standard-of-care chemotherapy  for  the :@0.084242:0.656709:0.480492:0.656709:0.480492:0.640953:0.084242:0.640953:0.007466:0.006523:0.013143:0.011738:0.013181:0.013143:0.005678:0.013181:0.006388:0.012604:0.006042:0.006388:0.012450:0.013143:0.005711:0.012508:0.011988:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.006642:0.006042:0.012604:0.005792:0.005330:0.006646:0.006523:0.011738:0.012508:0.005330
past 15 years. Ovarian cancer, by its na-:@0.084242:0.673153:0.475117:0.673153:0.475117:0.657397:0.084242:0.657397:0.013123:0.013143:0.007466:0.006523:0.007966:0.010660:0.010660:0.007978:0.010314:0.012508:0.013143:0.005792:0.007466:0.005330:0.007966:0.016722:0.010660:0.013143:0.005792:0.003848:0.013143:0.011738:0.007966:0.012450:0.013143:0.011738:0.012450:0.012508:0.003764:0.005330:0.007966:0.013123:0.010314:0.007966:0.003848:0.006523:0.007466:0.007966:0.011738:0.013143:0.006388
ture, is known to be a highly vascular tu-:@0.084242:0.689596:0.475154:0.689596:0.475154:0.673841:0.084242:0.673841:0.006523:0.011699:0.005707:0.012508:0.005330:0.007620:0.003848:0.007466:0.007620:0.009660:0.011738:0.012604:0.015990:0.011738:0.007610:0.006523:0.012604:0.007620:0.013123:0.012508:0.007620:0.013143:0.007620:0.011738:0.003848:0.012950:0.011738:0.003848:0.010314:0.007620:0.010660:0.013143:0.007466:0.012450:0.011699:0.003848:0.013143:0.005792:0.007620:0.006523:0.011699:0.006388
mour. The addition of bevacizumab as an-:@0.084242:0.706040:0.475160:0.706040:0.475160:0.690284:0.084242:0.690284:0.018049:0.012604:0.011699:0.004372:0.005330:0.004647:0.008197:0.011738:0.012508:0.004657:0.013143:0.013181:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.004643:0.012604:0.006042:0.004645:0.013123:0.012508:0.010660:0.013143:0.012450:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.004657:0.013143:0.007466:0.004657:0.013143:0.011738:0.006388
ti-angiogeneic agent has recently been :@0.084242:0.722484:0.480480:0.722484:0.480480:0.706728:0.084242:0.706728:0.006523:0.003848:0.006388:0.013143:0.011738:0.012950:0.003848:0.012604:0.012950:0.012508:0.011738:0.012508:0.003848:0.012450:0.009794:0.013143:0.012950:0.012508:0.011738:0.006523:0.009794:0.011738:0.013143:0.007466:0.009794:0.005713:0.012508:0.012450:0.012508:0.011738:0.006523:0.003848:0.010314:0.009794:0.013123:0.012508:0.012508:0.011738:0.005330
tested in two large phase III studies.:@0.084242:0.738928:0.412922:0.738928:0.412922:0.723172:0.084242:0.723172:0.006523:0.012508:0.007466:0.006523:0.012508:0.013181:0.005330:0.003848:0.011738:0.005330:0.006523:0.015990:0.012604:0.005330:0.003848:0.013143:0.005792:0.012950:0.012508:0.005330:0.013123:0.011738:0.013143:0.007466:0.012508:0.005330:0.004349:0.004349:0.004349:0.005330:0.007466:0.006523:0.011699:0.013181:0.003848:0.012508:0.007466:0.005330
Both the GOG 218 trial and the ICON :@0.102426:0.755372:0.480440:0.755372:0.480440:0.739616:0.102426:0.739616:0.011430:0.012989:0.006908:0.012123:0.007774:0.006908:0.012123:0.012892:0.007774:0.017164:0.017106:0.017164:0.007774:0.011045:0.011045:0.011045:0.007774:0.006908:0.006177:0.004233:0.013527:0.004233:0.007774:0.013527:0.012123:0.013566:0.007774:0.006908:0.012123:0.012892:0.007774:0.004734:0.016029:0.017106:0.014236:0.005330
7 trial demonstrated no overall survival :@0.084242:0.771816:0.480505:0.771816:0.480505:0.756060:0.084242:0.756060:0.011045:0.009390:0.006908:0.006177:0.004233:0.013527:0.004233:0.009390:0.013566:0.012892:0.018434:0.012989:0.012123:0.007851:0.006908:0.006177:0.013527:0.006908:0.012892:0.013566:0.009390:0.012123:0.012989:0.009390:0.012989:0.011045:0.012892:0.006177:0.013527:0.004233:0.004233:0.009390:0.007851:0.012084:0.006177:0.011045:0.004233:0.011045:0.013527:0.003852:0.005330
benefit.:@0.084242:0.788260:0.157652:0.788260:0.157652:0.772504:0.084242:0.772504:0.013508:0.012892:0.012123:0.012892:0.004878:0.004878:0.006908:0.005330
12,13:@0.158024:0.782635:0.186889:0.782635:0.186889:0.773449:0.158024:0.773449:0.006439:0.006439:0.003332:0.006439:0.006215
 Both studies added beva-:@0.187120:0.788254:0.475160:0.788254:0.475160:0.772498:0.187120:0.772498:0.013681:0.011430:0.012989:0.006908:0.012123:0.013681:0.007851:0.006908:0.012084:0.013566:0.004233:0.012892:0.007851:0.013681:0.013527:0.013566:0.013566:0.012892:0.013566:0.013681:0.013508:0.012892:0.011045:0.013527:0.006388
cizumab to the carboplatin/paclitaxel :@0.084251:0.804698:0.480475:0.804698:0.480475:0.788942:0.084251:0.788942:0.012835:0.004233:0.008563:0.012084:0.018434:0.013527:0.013508:0.012796:0.006908:0.012989:0.012796:0.006908:0.012123:0.012892:0.012796:0.012835:0.013527:0.006177:0.013508:0.012989:0.013508:0.004233:0.013527:0.006908:0.004233:0.012123:0.008794:0.013508:0.013527:0.012835:0.004233:0.004233:0.006908:0.013527:0.009621:0.012892:0.003852:0.005330
backbone, although the dose differed: :@0.084251:0.821142:0.480540:0.821142:0.480540:0.805386:0.084251:0.805386:0.013508:0.013527:0.012835:0.010045:0.013508:0.012989:0.012123:0.012892:0.005715:0.008948:0.013527:0.004233:0.006908:0.012123:0.012989:0.012084:0.013335:0.012123:0.008948:0.006908:0.012123:0.012892:0.008948:0.013566:0.012989:0.007851:0.012892:0.008948:0.013566:0.004233:0.006483:0.006427:0.012892:0.006098:0.012892:0.013566:0.005326:0.005330
15 mg/kg in the GOG 218 and 7.5  mg/:@0.084251:0.837586:0.475179:0.837586:0.475179:0.821830:0.084251:0.821830:0.011045:0.011045:0.005715:0.018434:0.013335:0.008794:0.010045:0.013335:0.008447:0.004233:0.012123:0.008447:0.006908:0.012123:0.012892:0.008447:0.017164:0.017106:0.017164:0.008447:0.011045:0.011045:0.011045:0.008447:0.013527:0.012123:0.013566:0.008447:0.011045:0.005715:0.011045:0.005330:0.003117:0.018434:0.013335:0.008409
kg in ICON 7. Other differences included :@0.084251:0.854029:0.480467:0.854029:0.480467:0.838273:0.084251:0.838273:0.010045:0.013335:0.005542:0.004233:0.012123:0.005542:0.004734:0.016029:0.017106:0.014624:0.005542:0.011045:0.005715:0.005542:0.017106:0.006908:0.012123:0.012892:0.006177:0.005542:0.013566:0.004233:0.006483:0.006427:0.012892:0.006098:0.012892:0.012123:0.012835:0.012892:0.007851:0.005542:0.004233:0.012123:0.012835:0.004233:0.012084:0.013566:0.012892:0.013181:0.005330
the cycle at which the bevacizumab :@0.084251:0.870473:0.480492:0.870473:0.480492:0.854717:0.084251:0.854717:0.006908:0.012123:0.012892:0.012334:0.012835:0.010699:0.012835:0.004233:0.012892:0.012334:0.013527:0.006908:0.012334:0.016375:0.012123:0.004233:0.012835:0.012123:0.012334:0.006908:0.012123:0.012892:0.012334:0.013508:0.012892:0.011045:0.013527:0.012835:0.004233:0.008563:0.012084:0.018434:0.013527:0.013125:0.005330
was initiated and the number of cycles :@0.084251:0.886917:0.480494:0.886917:0.480494:0.871161:0.084251:0.871161:0.016375:0.013527:0.007851:0.007966:0.004233:0.012123:0.004233:0.006908:0.004233:0.013527:0.006908:0.012892:0.013566:0.007966:0.013527:0.012123:0.013566:0.007966:0.006908:0.012123:0.012892:0.007966:0.012123:0.012084:0.018434:0.013508:0.012892:0.006177:0.007966:0.012989:0.006427:0.007966:0.012835:0.010699:0.012835:0.004233:0.012892:0.007470:0.005330
(months) the bevacizumab was contin-:@0.084251:0.903361:0.475179:0.903361:0.475179:0.887605:0.084251:0.887605:0.007485:0.018434:0.012989:0.012123:0.006908:0.012123:0.007851:0.007485:0.008524:0.006908:0.012123:0.012892:0.008524:0.013508:0.012892:0.011045:0.013527:0.012835:0.004233:0.008563:0.012084:0.018434:0.013527:0.013508:0.008524:0.016375:0.013527:0.007851:0.008524:0.012835:0.012989:0.012123:0.006908:0.004233:0.012123:0.006388
ued (16 cycles in GOG 218 and 12 cycles :@0.084251:0.919805:0.480417:0.919805:0.480417:0.904049:0.084251:0.904049:0.012084:0.012892:0.013566:0.004772:0.007485:0.011045:0.011045:0.004772:0.012835:0.010699:0.012835:0.004233:0.012892:0.007851:0.004772:0.004233:0.012123:0.004772:0.017164:0.017106:0.017164:0.004772:0.011045:0.011045:0.011045:0.004772:0.013527:0.012123:0.013566:0.004772:0.011045:0.011045:0.004772:0.012835:0.010699:0.012835:0.004233:0.012892:0.007470:0.005330
in ICON 7).:@0.084251:0.936249:0.188390:0.936249:0.188390:0.920493:0.084251:0.920493:0.004233:0.012123:0.005715:0.004734:0.016029:0.017106:0.014624:0.005715:0.011045:0.007485:0.005330
Despite these differences, there was a :@0.523651:0.096170:0.919898:0.096170:0.919898:0.080414:0.523651:0.080414:0.014316:0.012508:0.007466:0.013123:0.003848:0.006523:0.012508:0.012354:0.006523:0.011738:0.012508:0.007466:0.012508:0.012354:0.013181:0.003848:0.006104:0.006042:0.012508:0.005709:0.012508:0.011738:0.012450:0.012508:0.007466:0.005330:0.012354:0.006523:0.011738:0.012508:0.005705:0.012508:0.012354:0.015990:0.013143:0.007466:0.012354:0.013143:0.005330
clear  benefit  in  progression-free  survival :@0.523651:0.112521:0.919865:0.112521:0.919865:0.096765:0.523651:0.096765:0.012450:0.003848:0.012508:0.013143:0.005792:0.005330:0.006119:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.005330:0.006108:0.003848:0.011738:0.005330:0.006119:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.006388:0.006042:0.005713:0.012508:0.012508:0.005330:0.006117:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330
in both studies, for  the arms containing :@0.523651:0.128873:0.919912:0.128873:0.919912:0.113117:0.523651:0.113117:0.003848:0.011738:0.010429:0.013123:0.012604:0.006523:0.011738:0.010429:0.007466:0.006523:0.011699:0.013181:0.003848:0.012508:0.007466:0.005330:0.010429:0.006042:0.012604:0.005792:0.005330:0.005088:0.006523:0.011738:0.012508:0.010429:0.013143:0.006325:0.018049:0.007466:0.010429:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950:0.005330
bevacizumab with chemotherapy and :@0.523651:0.145224:0.919875:0.145224:0.919875:0.129468:0.523651:0.129468:0.013123:0.012508:0.010660:0.013143:0.012450:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.014778:0.015990:0.003848:0.006523:0.011738:0.014778:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011722:0.012508:0.005792:0.013143:0.013123:0.010314:0.014778:0.013143:0.011738:0.013181:0.005330
followed by maintenance bevacizumab. :@0.523651:0.161575:0.919883:0.161575:0.919883:0.145819:0.523651:0.145819:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.012508:0.013181:0.008063:0.013123:0.010314:0.008074:0.018049:0.013143:0.003848:0.011738:0.006523:0.012508:0.011738:0.013143:0.011738:0.012450:0.012508:0.008063:0.013123:0.012508:0.010660:0.013143:0.012450:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.005330:0.005330
Unfortunately, there was no clear overall :@0.523651:0.177926:0.919889:0.177926:0.919889:0.162170:0.523651:0.162170:0.012604:0.011738:0.006042:0.012604:0.005792:0.006523:0.011699:0.011738:0.013143:0.006523:0.012508:0.003848:0.010314:0.005330:0.008070:0.006523:0.011738:0.012508:0.005705:0.012508:0.008090:0.015990:0.013143:0.007466:0.008101:0.011738:0.012604:0.008084:0.012450:0.003848:0.012508:0.013143:0.005792:0.008091:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.005330
survival benefit.:@0.523651:0.194278:0.667199:0.194278:0.667199:0.178522:0.523651:0.178522:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.005330
In  a  subset  of  patients  with  high-risk :@0.541835:0.210629:0.919890:0.210629:0.919890:0.194873:0.541835:0.194873:0.004541:0.011930:0.005330:0.006952:0.013335:0.005330:0.006954:0.007658:0.011892:0.013316:0.007658:0.012700:0.006716:0.005330:0.006952:0.012796:0.006235:0.005330:0.006952:0.013316:0.013335:0.006716:0.004041:0.012700:0.011930:0.006716:0.007658:0.005330:0.006952:0.016183:0.004041:0.006716:0.011930:0.005330:0.006954:0.011930:0.004041:0.013143:0.011930:0.006581:0.005984:0.004041:0.007658:0.009660:0.005330
disease, a survival benefit was seen. Fol-:@0.523651:0.226980:0.914549:0.226980:0.914549:0.211224:0.523651:0.211224:0.013373:0.004041:0.007658:0.012700:0.013335:0.007658:0.012700:0.005523:0.007426:0.013335:0.007426:0.007658:0.011892:0.005984:0.010853:0.004041:0.010853:0.013335:0.004041:0.007426:0.013316:0.012700:0.011930:0.012700:0.004782:0.004782:0.006716:0.007426:0.016183:0.013335:0.007658:0.007426:0.007658:0.012700:0.012700:0.011930:0.005523:0.007426:0.009525:0.012796:0.004041:0.006388
lowing the results of two trials with beva-:@0.523651:0.243331:0.914556:0.243331:0.914556:0.227575:0.523651:0.227575:0.004041:0.012796:0.016183:0.004041:0.011930:0.013143:0.006985:0.006716:0.011930:0.012700:0.006985:0.005904:0.012700:0.007658:0.011892:0.004041:0.006716:0.007658:0.006985:0.012796:0.006235:0.006985:0.006716:0.016183:0.012796:0.006985:0.006716:0.005984:0.004041:0.013335:0.004041:0.007658:0.006985:0.016183:0.004041:0.006716:0.011930:0.006985:0.013316:0.012700:0.010853:0.013335:0.006388
cizumab, research with multiple new :@0.523651:0.259683:0.919890:0.259683:0.919890:0.243927:0.523651:0.243927:0.012642:0.004041:0.008370:0.011892:0.018242:0.013335:0.013316:0.005523:0.016587:0.005905:0.012700:0.007658:0.012700:0.013335:0.005850:0.012642:0.011930:0.016587:0.016183:0.004041:0.006716:0.011930:0.016587:0.018242:0.011892:0.004041:0.006716:0.004041:0.013316:0.004041:0.012700:0.016587:0.011930:0.012700:0.015992:0.005330
agents, including tyrosine kinase inhibitors:@0.523651:0.276034:0.914578:0.276034:0.914578:0.260278:0.523651:0.260278:0.013335:0.013143:0.012700:0.011930:0.006716:0.007658:0.005523:0.004714:0.004041:0.011930:0.012642:0.004041:0.011892:0.013373:0.004041:0.011930:0.013143:0.004714:0.006716:0.010506:0.005905:0.012796:0.007658:0.004041:0.011930:0.012700:0.004714:0.009852:0.004041:0.011930:0.013335:0.007658:0.012700:0.004714:0.004041:0.011930:0.011930:0.004041:0.013316:0.004041:0.006716:0.012796:0.005984:0.007466
 :@0.914560:0.276034:0.919890:0.276034:0.919890:0.260278:0.914560:0.260278:0.005330
(TKIs), is ongoing.:@0.523651:0.292385:0.683767:0.292385:0.683767:0.276629:0.523651:0.276629:0.007293:0.008390:0.011565:0.004541:0.007658:0.007293:0.005523:0.005523:0.004041:0.007658:0.005523:0.012796:0.011930:0.013143:0.012796:0.004041:0.011930:0.013143:0.005330
RELAPSED OVARIAN CANCER:@0.523636:0.325808:0.850543:0.325808:0.850543:0.306211:0.523636:0.306211:0.013641:0.012230:0.010348:0.017404:0.013170:0.012230:0.012230:0.016463:0.006585:0.019756:0.016463:0.017404:0.013641:0.006585:0.017404:0.017404:0.006585:0.018344:0.017404:0.017404:0.018344:0.012230:0.013641
The majority (80%) of patients with ovarian :@0.523636:0.344458:0.919868:0.344458:0.919868:0.328702:0.523636:0.328702:0.008197:0.011738:0.012508:0.005215:0.018049:0.013143:0.003906:0.012604:0.005792:0.003848:0.006523:0.010314:0.005215:0.007100:0.010660:0.010672:0.014913:0.007100:0.005215:0.012604:0.006042:0.005215:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005215:0.015990:0.003848:0.006523:0.011738:0.005215:0.012604:0.010660:0.013143:0.005792:0.003848:0.013143:0.011738:0.005330
cancer will suffer a relapse. The choice of :@0.523636:0.360809:0.919885:0.360809:0.919885:0.345053:0.523636:0.345053:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.006027:0.015990:0.003848:0.003848:0.003848:0.006042:0.007466:0.011699:0.006100:0.006042:0.012508:0.005792:0.006027:0.013143:0.006042:0.005711:0.012508:0.003848:0.013143:0.013123:0.007466:0.012508:0.005330:0.006042:0.008197:0.011738:0.012508:0.006025:0.012450:0.011738:0.012604:0.003848:0.012450:0.012508:0.006027:0.012604:0.006042:0.005330
subsequent lines of chemotherapy is then :@0.523636:0.377160:0.919864:0.377160:0.919864:0.361404:0.523636:0.361404:0.007466:0.011699:0.013123:0.007466:0.012508:0.013123:0.011699:0.012508:0.011738:0.006523:0.006138:0.003848:0.003848:0.011738:0.012508:0.007466:0.006138:0.012604:0.006042:0.006138:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.006127:0.003848:0.007466:0.006138:0.006523:0.011738:0.012508:0.011738:0.005330
determined by the platinum-free interval. :@0.523636:0.393512:0.919864:0.393512:0.919864:0.377756:0.523636:0.377756:0.013181:0.012508:0.006523:0.012508:0.006317:0.018049:0.003848:0.011738:0.012508:0.013181:0.006956:0.013123:0.010314:0.006954:0.006523:0.011738:0.012508:0.006948:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388:0.006042:0.005711:0.012508:0.012508:0.006952:0.003848:0.011738:0.006523:0.012508:0.005792:0.010660:0.013143:0.003848:0.005330:0.005330
This is defined as the time interval from the :@0.523636:0.409863:0.919883:0.409863:0.919883:0.394107:0.523636:0.394107:0.008197:0.011738:0.003848:0.007466:0.005292:0.003848:0.007466:0.005297:0.013181:0.012508:0.004686:0.004686:0.011738:0.012508:0.013181:0.005284:0.013143:0.007466:0.005296:0.006523:0.011738:0.012508:0.005284:0.006523:0.003848:0.018049:0.012508:0.005290:0.003848:0.011738:0.006523:0.012508:0.005792:0.010660:0.013143:0.003848:0.005296:0.006042:0.005713:0.012604:0.018049:0.005286:0.006523:0.011738:0.012508:0.005330
last platinum dose until progressive  dis-:@0.523636:0.426214:0.914528:0.426214:0.914528:0.410458:0.523636:0.410458:0.003848:0.013143:0.007466:0.006523:0.011815:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.011815:0.013181:0.012604:0.007466:0.012508:0.011815:0.011699:0.011738:0.006523:0.003848:0.003848:0.011815:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.010660:0.012508:0.005330:0.006496:0.013181:0.003848:0.007466:0.006388
ease. In general, those patients with plat-:@0.523636:0.442565:0.914561:0.442565:0.914561:0.426809:0.523636:0.426809:0.012508:0.013143:0.007466:0.012508:0.005330:0.006542:0.004349:0.011738:0.006542:0.012950:0.012508:0.011738:0.012508:0.005792:0.013131:0.003848:0.005330:0.006542:0.006523:0.011738:0.012604:0.007466:0.012508:0.006531:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.006542:0.015990:0.003848:0.006523:0.011738:0.006542:0.013123:0.003848:0.013143:0.006523:0.006388
inum-refractory  or  resistant disease have :@0.523636:0.458917:0.919883:0.458917:0.919883:0.443161:0.523636:0.443161:0.003848:0.011738:0.011699:0.018049:0.006388:0.005713:0.012508:0.006042:0.005792:0.013143:0.012450:0.006523:0.012604:0.005792:0.010314:0.005330:0.003862:0.012604:0.005792:0.005330:0.003866:0.005713:0.012508:0.007466:0.003848:0.007466:0.006523:0.013143:0.011738:0.006523:0.009217:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.009217:0.011738:0.013143:0.010660:0.012508:0.005330
a poor prognosis and do not benefit from :@0.523636:0.475268:0.919879:0.475268:0.919879:0.459512:0.523636:0.459512:0.013143:0.006185:0.013123:0.012604:0.012604:0.005792:0.006173:0.013123:0.005715:0.012604:0.012950:0.011738:0.012590:0.007466:0.003848:0.007466:0.006192:0.013143:0.011738:0.013181:0.006183:0.013181:0.012604:0.006181:0.011738:0.012604:0.006523:0.006173:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.006173:0.006042:0.005711:0.012604:0.018049:0.005330
the re-introduction of a platinum-contain-:@0.523636:0.491619:0.914551:0.491619:0.914551:0.475863:0.523636:0.475863:0.006523:0.011738:0.012508:0.006119:0.005713:0.012508:0.006388:0.003848:0.011738:0.006523:0.005709:0.012604:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.006121:0.012604:0.006042:0.006121:0.013143:0.006129:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.006388
ing regimen. The response rates of liposo-:@0.523636:0.507970:0.914551:0.507970:0.914551:0.492214:0.523636:0.492214:0.003848:0.011738:0.012950:0.006702:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.005330:0.006696:0.008197:0.011738:0.012508:0.006700:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.006704:0.005792:0.013143:0.006523:0.012508:0.007466:0.006706:0.012604:0.006042:0.006698:0.003848:0.003848:0.013123:0.012604:0.007466:0.012604:0.006388
mal doxorubicin, topotecan, paclitaxel :@0.523636:0.524322:0.919860:0.524322:0.919860:0.508566:0.523636:0.508566:0.018049:0.013143:0.003848:0.014066:0.013181:0.012604:0.009236:0.012604:0.005792:0.011699:0.013123:0.003848:0.012450:0.003848:0.011738:0.005330:0.014066:0.006523:0.012604:0.013123:0.012604:0.006523:0.012508:0.012450:0.013143:0.011722:0.005330:0.014066:0.013123:0.013143:0.012450:0.003848:0.003848:0.006523:0.013143:0.009236:0.012508:0.003848:0.005330
and gemcitabine are similar in this setting.:@0.523636:0.540673:0.913770:0.540673:0.913770:0.524917:0.523636:0.524917:0.013143:0.011738:0.013181:0.005330:0.012950:0.012508:0.018049:0.012450:0.003848:0.006523:0.013143:0.013123:0.003848:0.011738:0.012508:0.005330:0.013143:0.005709:0.012508:0.005330:0.007466:0.003848:0.018049:0.003848:0.003848:0.013143:0.005792:0.005330:0.003848:0.011738:0.005330:0.006523:0.011738:0.003848:0.007466:0.005330:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950:0.005330
The re-introduction of a platinum-based :@0.541820:0.557024:0.919868:0.557024:0.919868:0.541268:0.541820:0.541268:0.008197:0.011738:0.012508:0.005907:0.005713:0.012508:0.006388:0.003848:0.011738:0.006523:0.005709:0.012604:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005907:0.012604:0.006042:0.005907:0.013143:0.005907:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388:0.013123:0.013143:0.007466:0.012508:0.013181:0.005330
regimen  is, however, recommended in :@0.523636:0.573375:0.919895:0.573375:0.919895:0.557619:0.523636:0.557619:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.005330:0.008111:0.003848:0.007466:0.005330:0.013450:0.011738:0.012604:0.015990:0.012508:0.010660:0.012508:0.003768:0.005330:0.013450:0.005711:0.012508:0.012450:0.012604:0.018049:0.018049:0.012508:0.011738:0.013181:0.012508:0.013181:0.013450:0.003848:0.011738:0.005330
patients with partially-sensitive tumours :@0.523636:0.589727:0.919893:0.589727:0.919893:0.573971:0.523636:0.573971:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.015856:0.015990:0.003848:0.006523:0.011738:0.015856:0.013123:0.013143:0.005792:0.006523:0.003848:0.013143:0.003848:0.003848:0.010314:0.006388:0.007466:0.012508:0.011738:0.007466:0.003848:0.006540:0.003848:0.010660:0.012508:0.015856:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.005330
and especially fully-sensitive tumours. Fol-:@0.523636:0.606078:0.914543:0.606078:0.914543:0.590322:0.523636:0.590322:0.013143:0.011738:0.013181:0.007428:0.012508:0.007466:0.013123:0.012508:0.012450:0.003848:0.013143:0.003848:0.003848:0.010327:0.007428:0.006042:0.011699:0.003848:0.003848:0.010314:0.006388:0.007466:0.012508:0.011738:0.007466:0.003848:0.006523:0.003848:0.010660:0.012508:0.007451:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.005330:0.007428:0.009333:0.012604:0.003848:0.006388
lowing the results of the CALYPSO study,  :@0.523636:0.622429:0.919875:0.622524:0.919875:0.606768:0.523636:0.606673:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.006914:0.006523:0.011738:0.012508:0.006908:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.007466:0.006927:0.012604:0.006042:0.006910:0.006523:0.011738:0.012508:0.006908:0.015644:0.014239:0.007135:0.011392:0.011392:0.009583:0.016722:0.006910:0.007466:0.006523:0.011699:0.013181:0.010314:0.005330:0.012426:-0.342571
14:@0.902110:0.616905:0.914540:0.616905:0.914540:0.607720:0.902110:0.607720:0.006215:0.006215
pegylated liposomal doxorubicin with car-:@0.523635:0.638875:0.914550:0.638875:0.914550:0.623119:0.523635:0.623119:0.013123:0.012508:0.012950:0.010314:0.003848:0.013143:0.006523:0.012508:0.013181:0.004580:0.003848:0.003848:0.013123:0.012604:0.007466:0.012604:0.018049:0.013143:0.003848:0.004570:0.013181:0.012604:0.009236:0.012604:0.005792:0.011699:0.013112:0.003848:0.012450:0.003848:0.011738:0.004580:0.015990:0.003848:0.006523:0.011738:0.004568:0.012450:0.013143:0.005792:0.006388
boplatin is often recommended, but other :@0.523635:0.655227:0.919902:0.655227:0.919902:0.639471:0.523635:0.639471:0.013123:0.012604:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.004791:0.003848:0.007466:0.004791:0.012604:0.006042:0.006523:0.012508:0.011738:0.004774:0.005713:0.012508:0.012450:0.012604:0.018049:0.018049:0.012508:0.011738:0.013181:0.012496:0.013181:0.005330:0.004791:0.013123:0.011699:0.006523:0.004791:0.012604:0.006523:0.011738:0.012508:0.005792:0.005330
regimens such as carboplatin and gemcit-:@0.523635:0.671578:0.914523:0.671578:0.914523:0.655822:0.523635:0.655822:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.007466:0.004407:0.007466:0.011699:0.012450:0.011738:0.004407:0.013143:0.007466:0.004407:0.012450:0.013143:0.005792:0.013123:0.012604:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.004407:0.013143:0.011738:0.013181:0.004407:0.012950:0.012508:0.018049:0.012450:0.003848:0.006523:0.006388
abine also show responses.:@0.523635:0.687929:0.774764:0.687929:0.774764:0.672173:0.523635:0.672173:0.013143:0.013123:0.003848:0.011738:0.012508:0.005330:0.013143:0.003848:0.007466:0.012604:0.005330:0.007466:0.011738:0.012604:0.015990:0.005330:0.005711:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.007466:0.005330
Finally, the  OCEANS  study  showed :@0.541819:0.704280:0.919882:0.704308:0.919882:0.688552:0.541819:0.688524:0.009333:0.003848:0.011738:0.013143:0.003848:0.003848:0.010314:0.005330:0.016183:0.006523:0.011738:0.012508:0.005330:0.010841:0.016722:0.015644:0.010314:0.014239:0.014239:0.009583:0.005330:0.010841:0.007466:0.006523:0.011699:0.013181:0.010314:0.012442:0.016183:0.007466:0.011738:0.012604:0.015990:0.012508:0.013181:-0.461538
13:@0.812448:0.698689:0.824878:0.698689:0.824878:0.689504:0.812448:0.689504:0.006215:0.006215
clear  progression-free  survival  benefit  of :@0.523643:0.720660:0.919874:0.720660:0.919874:0.704904:0.523643:0.704904:0.012450:0.003848:0.012508:0.013143:0.005792:0.005330:0.005357:0.013123:0.005713:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.006388:0.006042:0.005705:0.012508:0.012508:0.005330:0.005353:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013154:0.003848:0.005330:0.005361:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.005330:0.005347:0.012604:0.006042:0.005330
the  addition of  bevacizumab chemo-:@0.523643:0.737011:0.914552:0.737011:0.914552:0.721255:0.523643:0.721255:0.006523:0.011738:0.012508:0.005330:0.009606:0.013143:0.013181:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.014951:0.012604:0.006042:0.005330:0.009610:0.013123:0.012508:0.010660:0.013143:0.012450:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.014951:0.012450:0.011738:0.012508:0.018049:0.012592:0.006388
therapy,  as did the  AURELIA  study,   the :@0.523643:0.753362:0.919881:0.753379:0.919881:0.737623:0.523643:0.737606:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330:0.004137:0.013143:0.007466:0.009487:0.013181:0.003848:0.013181:0.009487:0.006523:0.011738:0.012508:0.005330:0.004135:0.014239:0.012604:0.011680:0.010314:0.008890:0.004349:0.014239:0.005330:0.004131:0.007466:0.006523:0.011699:0.013181:0.010314:0.005330:0.012412:0.005330:0.004143:0.006523:0.011738:0.012508:-0.532912
15:@0.861875:0.747760:0.874305:0.747760:0.874305:0.738574:0.861875:0.738574:0.006215:0.006215
latter study being in the refractory setting. :@0.523636:0.769730:0.919872:0.769730:0.919872:0.753974:0.523636:0.753974:0.003848:0.013143:0.006523:0.006523:0.012508:0.005792:0.005850:0.007466:0.006523:0.011699:0.013181:0.010314:0.005850:0.013123:0.012508:0.003848:0.011738:0.012950:0.005850:0.003848:0.011738:0.005850:0.006523:0.011738:0.012508:0.005850:0.005711:0.012508:0.006042:0.005792:0.013143:0.012450:0.006523:0.012604:0.005792:0.010314:0.005850:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950:0.005330:0.005330
In both studies, bevacizumab was added :@0.523636:0.786081:0.919856:0.786081:0.919856:0.770325:0.523636:0.770325:0.004349:0.011738:0.006215:0.013123:0.012604:0.006523:0.011738:0.006215:0.007466:0.006523:0.011699:0.013181:0.003848:0.012508:0.007466:0.005330:0.006215:0.013123:0.012508:0.010660:0.013143:0.012450:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.006215:0.015990:0.013143:0.007466:0.006215:0.013143:0.013181:0.013181:0.012508:0.013181:0.005330
to a chemotherapy backbone and con-:@0.523636:0.802433:0.914555:0.802433:0.914555:0.786677:0.523636:0.786677:0.006523:0.012604:0.007716:0.013143:0.007716:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.007707:0.013123:0.013143:0.012450:0.009660:0.013123:0.012604:0.011738:0.012508:0.007716:0.013143:0.011738:0.013181:0.007716:0.012450:0.012604:0.011738:0.006388
tinued until disease progression.:@0.523636:0.818784:0.817956:0.818784:0.817956:0.803028:0.523636:0.803028:0.006523:0.003848:0.011738:0.011699:0.012508:0.013181:0.005330:0.011699:0.011738:0.006523:0.003848:0.003848:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.013123:0.005713:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330
CANCER OF THE CERVIX:@0.523636:0.852167:0.793158:0.852167:0.793158:0.832570:0.523636:0.832570:0.018344:0.017404:0.017404:0.018344:0.012230:0.013641:0.006585:0.019756:0.011289:0.006585:0.009878:0.015993:0.012230:0.006585:0.018344:0.012230:0.013641:0.016463:0.006585:0.015993
Squamous carcinoma of the cervix is the :@0.523636:0.870816:0.919868:0.870816:0.919868:0.855061:0.523636:0.855061:0.009583:0.013123:0.011699:0.013143:0.018049:0.012604:0.011699:0.007466:0.007408:0.012450:0.013143:0.005657:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.007408:0.012604:0.006042:0.007408:0.006523:0.011738:0.012508:0.007408:0.012450:0.012508:0.005792:0.010660:0.003848:0.009236:0.007408:0.003848:0.007466:0.007420:0.006523:0.011738:0.012508:0.005330
most common histological subtype. Other :@0.523636:0.887168:0.919895:0.887168:0.919895:0.871412:0.523636:0.871412:0.018049:0.012604:0.007466:0.006523:0.005638:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.005638:0.011738:0.003848:0.007466:0.006523:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.005638:0.007466:0.011699:0.013123:0.006523:0.010314:0.013123:0.012508:0.005330:0.005638:0.016722:0.006523:0.011738:0.012508:0.005792:0.005330
histological subtypes include adenocar-:@0.523636:0.903519:0.914545:0.903519:0.914545:0.887763:0.523636:0.887763:0.011738:0.003848:0.007466:0.006523:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.011199:0.007466:0.011699:0.013123:0.006523:0.010314:0.013123:0.012508:0.007466:0.011199:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.011199:0.013143:0.013181:0.012508:0.011738:0.012604:0.012450:0.013143:0.005792:0.006388
cinoma  and  small-cell carcinoma.  The :@0.523636:0.919870:0.919875:0.919870:0.919875:0.904114:0.523636:0.904114:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330:0.008357:0.013143:0.011738:0.013181:0.005330:0.008361:0.007466:0.018049:0.013143:0.003848:0.003848:0.006388:0.012450:0.012508:0.003848:0.003848:0.013701:0.012450:0.013143:0.005657:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330:0.005330:0.008355:0.008197:0.011738:0.012508:0.005330
mainstay of cancer of the cervix remains :@0.523636:0.936221:0.919874:0.936221:0.919874:0.920466:0.523636:0.920466:0.018049:0.013143:0.003848:0.011738:0.007466:0.006523:0.013143:0.010314:0.007274:0.012604:0.006042:0.007262:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007256:0.012604:0.006042:0.007262:0.006523:0.011738:0.012508:0.007258:0.012450:0.012508:0.005792:0.010660:0.003848:0.009236:0.007274:0.005711:0.012508:0.018049:0.013143:0.003848:0.011738:0.007466:0.005330